273 related articles for article (PubMed ID: 22850059)
1. Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens.
Strecker T; Uhlendorff J; Diederich S; Lenz-Bauer C; Trusheim H; Roth B; Kolesnikova L; Aepinus C; Dornow R; Gerlach J; Matrosovich M; Valley U; Eickmann M; Becker S
Clin Chem Lab Med; 2012 May; 50(7):1275-9. PubMed ID: 22850059
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs.
Wen F; Yu H; Yang FR; Huang M; Yang S; Zhou YJ; Li ZJ; Tong GZ
Arch Virol; 2014 Nov; 159(11):2957-67. PubMed ID: 24957653
[TBL] [Abstract][Full Text] [Related]
3. The development of vaccine viruses against pandemic A(H1N1) influenza.
Robertson JS; Nicolson C; Harvey R; Johnson R; Major D; Guilfoyle K; Roseby S; Newman R; Collin R; Wallis C; Engelhardt OG; Wood JM; Le J; Manojkumar R; Pokorny BA; Silverman J; Devis R; Bucher D; Verity E; Agius C; Camuglia S; Ong C; Rockman S; Curtis A; Schoofs P; Zoueva O; Xie H; Li X; Lin Z; Ye Z; Chen LM; O'Neill E; Balish A; Lipatov AS; Guo Z; Isakova I; Davis CT; Rivailler P; Gustin KM; Belser JA; Maines TR; Tumpey TM; Xu X; Katz JM; Klimov A; Cox NJ; Donis RO
Vaccine; 2011 Feb; 29(9):1836-43. PubMed ID: 21199698
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1.
Tsukamoto M; Hiroi S; Adachi K; Kato H; Inai M; Konishi I; Tanaka M; Yamamoto R; Sawa M; Handharyani E; Tsukamoto Y
Mol Med Rep; 2011; 4(2):209-14. PubMed ID: 21468553
[TBL] [Abstract][Full Text] [Related]
5. Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment.
Yu W; Yang F; Yang J; Ma L; Cun Y; Song S; Liao G
J Med Virol; 2016 Nov; 88(11):1914-21. PubMed ID: 27101353
[TBL] [Abstract][Full Text] [Related]
6. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
Collin N; de Radiguès X;
Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
[TBL] [Abstract][Full Text] [Related]
7. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.
Abelin A; Colegate T; Gardner S; Hehme N; Palache A
Vaccine; 2011 Feb; 29(6):1135-8. PubMed ID: 21115061
[TBL] [Abstract][Full Text] [Related]
8. Live attenuated influenza A virus vaccine protects against A(H1N1)pdm09 heterologous challenge without vaccine associated enhanced respiratory disease.
Gauger PC; Loving CL; Khurana S; Lorusso A; Perez DR; Kehrli ME; Roth JA; Golding H; Vincent AL
Virology; 2014 Dec; 471-473():93-104. PubMed ID: 25461535
[TBL] [Abstract][Full Text] [Related]
9. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.
Montomoli E; Khadang B; Piccirella S; Trombetta C; Mennitto E; Manini I; Stanzani V; Lapini G
Expert Rev Vaccines; 2012 May; 11(5):587-94. PubMed ID: 22827244
[TBL] [Abstract][Full Text] [Related]
10. Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.
Medina J; Boukhebza H; De Saint Jean A; Sodoyer R; Legastelois I; Moste C
Vaccine; 2015 Aug; 33(35):4221-7. PubMed ID: 26206270
[TBL] [Abstract][Full Text] [Related]
11. Continuous cell lines as a production system for influenza vaccines.
Genzel Y; Reichl U
Expert Rev Vaccines; 2009 Dec; 8(12):1681-92. PubMed ID: 19943763
[TBL] [Abstract][Full Text] [Related]
12. Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness.
Kim EH; Kwon HI; Park SJ; Kim YI; Si YJ; Lee IW; Kim SM; Kim SI; Ahn DH; Choi YK
J Microbiol Biotechnol; 2018 Jun; 28(6):997-1006. PubMed ID: 29642288
[TBL] [Abstract][Full Text] [Related]
13. Swine flu outbreak. Devilish dilemmas surround pandemic flu vaccine.
Enserink M; Kaiser J
Science; 2009 May; 324(5928):702-5. PubMed ID: 19423782
[No Abstract] [Full Text] [Related]
14. Virus of the year. The novel H1N1 influenza.
Enserink M; Cohen J
Science; 2009 Dec; 326(5960):1607. PubMed ID: 20019257
[No Abstract] [Full Text] [Related]
15. Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity.
Hütter J; Rödig JV; Höper D; Seeberger PH; Reichl U; Rapp E; Lepenies B
J Immunol; 2013 Jan; 190(1):220-30. PubMed ID: 23225881
[TBL] [Abstract][Full Text] [Related]
16. Synthetic generation of influenza vaccine viruses for rapid response to pandemics.
Dormitzer PR; Suphaphiphat P; Gibson DG; Wentworth DE; Stockwell TB; Algire MA; Alperovich N; Barro M; Brown DM; Craig S; Dattilo BM; Denisova EA; De Souza I; Eickmann M; Dugan VG; Ferrari A; Gomila RC; Han L; Judge C; Mane S; Matrosovich M; Merryman C; Palladino G; Palmer GA; Spencer T; Strecker T; Trusheim H; Uhlendorff J; Wen Y; Yee AC; Zaveri J; Zhou B; Becker S; Donabedian A; Mason PW; Glass JI; Rappuoli R; Venter JC
Sci Transl Med; 2013 May; 5(185):185ra68. PubMed ID: 23677594
[TBL] [Abstract][Full Text] [Related]
17. [Swine influenza virus: evolution mechanism and epidemic characterization--a review].
Qi X; Lu C
Wei Sheng Wu Xue Bao; 2009 Sep; 49(9):1138-45. PubMed ID: 20030049
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method.
Long Y; Ma L; Liu Z; Song S; Geng X; Yang F; Guo Q; Li Z; Li W; Liao G
Hum Vaccin Immunother; 2018 Mar; 14(3):615-622. PubMed ID: 29064728
[TBL] [Abstract][Full Text] [Related]
19. [Influenza vaccine: globalization of public health stakes].
Collin N; Briand S
Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
[TBL] [Abstract][Full Text] [Related]
20. A note on the use of influenza vaccination strategies when supply is limited.
Lee S; Morales R; Castillo-Chavez C
Math Biosci Eng; 2011 Jan; 8(1):171-82. PubMed ID: 21361406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
